Zydus Lifesciences Share Price (ZYDUSLIFE)
as on
| Source : NSE
Zydus Lifesciences Stock Performance
as on August 20, 2025 at 4:01 PM IST
Day's Low
Day's High
₹978.35₹991.85
0.50%
Downside
0.87%
Upside
52 Week's Low
52 Week's High
₹795₹1,22019.15%
Downside
24.07%
Upside
| Market Stats | |
| Previous Close | ₹989.45 |
| Open | ₹989.95 |
| Volume | 5.35L |
| Upper Circuit | ₹1,088.35 |
| Lower Circuit | ₹890.50 |
| Day's Low | ₹978.35 |
| Day's High | ₹991.85 |
| 52 Week Low | ₹795 |
| 52 Week High | ₹1,220 |
| Returns % | |
| 1 Month Return | + 2.01 % |
| 3 Month Return | + 12.02 % |
| 1 Year Return | -17.04 % |
| 3 Year Return | + 158.17 % |
| 5 Year Return | + 148.32 % |
Zydus Lifesciences Stock Fundamentals & Key Indicators
Check Zydus Lifesciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹99,561.82 Cr
Return on Equity (ROE)
31.29
PE Ratio (TTM)
21.77
Return on capital employed (ROCE)
30.47
Industry PE ratio
43.53
Beta (LTM)
0.75
P/B Ratio
4.2
Dividend Yield
1.24
PEG Ratio
5.53
Quarterly Earnings Growth YOY
1.57
EPS (TTM)
45.87
Sector
Pharmaceuticals
Book Value
238.1
Technical Analysis
Bullish
View Technical Analysis
Zydus Lifesciences Stock's Interest Amongst Investors
Zydus Lifesciences Stock Valuation
Track how Zydus Lifesciences P/E has moved over time to understand its valuation trends.
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (21.77x)
August 19, 2025
Industry (43.53x)
August 19, 2025
Highest (34.62x)
March 26, 2024
Today’s Price to Earnings Ratio: 21.77x
Zydus Lifesciences Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Zydus Lifesciences.
based on 30 analysts
36.67%
Buy
40.00%
Hold
23.33%
Sell
40% of analysts recommend a 'HOLD' rating for Zydus Lifesciences. Average target price of ₹1002.83
Source: S&P Global Market Intelligence
Zydus Lifesciences Share Price Target
Get share price movements and forecasts by analysts on Zydus Lifesciences.
Zydus Lifesciences price forecast by 30 analysts
Upside of1.35%
High
₹1150
Target
₹1002.83
Low
₹850
Zydus Lifesciences target price ₹1002.83, a slight upside of 1.35% compared to current price of ₹983.3. According to 30 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:12.11%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Financial Results
Get the annual and quarterly financial summary of Zydus Lifesciences Ltd, including revenue, profit, loss and more.
Zydus Lifesciences Earnings and Dividends
View detailed summary of the earnings and dividend history of Zydus Lifesciences.
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 3.3% since last year same period to ₹1,466.80Cr in the Q1 2025-2026. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 25.27% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2025
In the quarter ending March 2025, Zydus Lifesciences Ltd has declared dividend of ₹11.00 per share on 19 May 2025 - translating a dividend yield of 1.11%.
Read More about Dividends
Indices Featuring Zydus Lifesciences Stock
Check stock indices that include Zydus Lifesciences.
Zydus Lifesciences Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Zydus Lifesciences.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.99% | 0.00 | |
| Foreign Institutions | 7.13% | ||
| Mutual Funds | 5.56% | ||
| Retail Investors | 6.74% | 0.85 | |
| Others | 5.58% | 19.99 |
Zydus Lifesciences Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Zydus Lifesciences with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 99,561.82 | 29.66% | 0.61 | 4,614 | 23,241 | |
| BUY | 11,915.72 | -7.7% | 0.52 | 413 | 2,013 | |
| BUY | 63,849.73 | 5.42% | 0.60 | 3,483 | 31,723 | |
| BUY | 70,263.13 | 19.2% | 0.00 | 1,414 | 6,445 | |
| BUY | 47,555.66 | 17.68% | 0.56 | 927 | 3,749 |
Zydus Lifesciences News & Key Events
Latest news and events in one place to help you make informed investing decisions in Zydus Lifesciences.
Zydus Lifesciences Reports Strong Q1 Amid FDA Inspections - 14 Aug, 2025
Zydus Lifesciences' Ahmedabad plant passed USFDA inspection with no observations, while the Baddi plant received four observations. The company reported a 3.3% rise in net profit and 6% revenue growth in Q1, leading to stock gains despite caution from analysts regarding execution risks and valuations.Zydus Lifesciences Faces FDA Observations, Plant Passes Inspection - 13 Aug, 2025
Zydus Lifesciences received four observations from a USFDA inspection at its Baddi plant but cleared the Ahmedabad SEZ II plant inspection. Analysts maintain mixed ratings.Zydus Lifesciences Reports Strong Q1 Financials - 12 Aug, 2025
Zydus Lifesciences posted a 5.9% revenue increase and a 3.7% rise in net profit for Q1 FY26, driven by strong domestic and international sales.Zydus Lifesciences Secures Multiple USFDA Approvals - 11 Aug, 2025
Zydus Lifesciences received USFDA approvals for Diltiazem Hydrochloride and Prucalopride tablets, enhancing its market presence. Despite mixed trends in sales, the outlook remains positive.Zydus Secures USFDA and Canadian Approvals - 08 Aug, 2025
Zydus Lifesciences received USFDA approval for Prucalopride Tablets, boosting its gastrointestinal offerings, and also secured its first Canadian NOC for ZDS-Varenicline tablets.Zydus Gains Canadian Approval for Smoking Cessation Tablets - 07 Aug, 2025
Zydus Lifesciences has received its first Notice of Compliance from Health Canada for ZDS-Varenicline tablets, which aid in smoking cessation. The product has potential annual sales of CAD 15 million in Canada.Zydus Acquires Majority Stake in Amplitude Surgical - 30 Jul, 2025
Zydus Lifesciences has successfully acquired an 85.6% stake in Amplitude Surgical for €256 million. A mandatory tender offer for remaining shares at €6.25 per share will follow.Zydus Receives USFDA Approval for Ibrutinib Tablets - 24 Jul, 2025
Zydus Lifesciences has obtained tentative approval from the USFDA for its generic Ibrutinib tablets, indicated for treating various blood cancers, with significant annual sales potential.Zydus Matoda Plant Receives USFDA Approval Recommendation - 17 Jul, 2025
Zydus Lifesciences' Matoda facility underwent a USFDA Remote Regulatory Assessment for Atorvastatin Calcium Tablets. The assessment concluded with no observations, recommending the site for approval.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 4 quarters, 911.2 Cr → 1.46K Cr (in ₹), with an average increase of 14.6% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, ZYDUSLIFE stock has moved up by 2.0%
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.68% to 6.74% in Jun 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 5.30K Cr → 6.72K Cr (in ₹), with an average increase of 7.2% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 28.7% return, outperforming this stock by 45.8%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.99% of holdings in Jun 2025 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 6.36% to 5.56% in Jun 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 7.32% to 7.13% in Jun 2025 quarter
About Zydus Lifesciences Ltd
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹6,467.00Cr as on June 2025 (Q1 FY26)
Net Profit: ₹1,486.60Cr as on June 2025 (Q1 FY26)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| CEO | Pankaj R Patel |
| E-voting on shares | Click here to vote |
Mutual Funds that own Zydus Lifesciences Stock
Check out the Mutual Funds with significant holdings in Zydus Lifesciences.
FAQs
What is Zydus Lifesciences share price today?
Zydus Lifesciences share price today stands at ₹983.3, Open: ₹989.95, Previous Close: ₹989.45, High: ₹991.85, Low: ₹978.35, 52 Week High: ₹1220, 52 Week Low: ₹795 as on .
How to buy Zydus Lifesciences shares ?
To buy Zydus Lifesciences shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for ZYDUSLIFE or Zydus Lifesciences Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Zydus Lifesciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Zydus Lifesciences?
Today's traded volume of Zydus Lifesciences is 5.35L. Which means that 5.35L shares of Zydus Lifesciences were bought and sold on the stock market during today's trading session.
What is Zydus Lifesciences's market cap today?
Today's market capitalisation of Zydus Lifesciences is ₹99,561.82 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Zydus Lifesciences?
Zydus Lifesciences’s 52 week high is ₹1220 and 52 week low is ₹795. The current share price of Zydus Lifesciences is ₹983.3, which is -19.40% down from its 52 week high and 23.69% up from its 52 week low.